No improvement in overall survival (OS) was observed with palbociclib (Verzenio) plus endocrine therapy versus capecitabine ...

Imaging technology developed and refined at the University of Waterloo promises better detection and treatment of breast cancer by more accurately pinpointing cancerous tissue.

Aditya Bardia, MD, MPH, FASCO, medical oncologist, UCLA Health, provides new insights on the role of TROP2-directed antibody drug conjugates (ADCs) for patients with breast cancer.

Breast cancer incidence trends in U.S. women under 40 vary by geography and supports incorporating location information with established risk factors into risk prediction, improving the ability to ...

Celcuity's gedatolisib, a dual PI3K/mTOR inhibitor, shows promise in Phase 3 breast cancer trials. Click here to read an ...

Health insurers no longer completely cover two breast cancer drugs for women with metastasised hormone receptive breast ...

Paolo Tarantino, MD, PhD, discusses elacestrant as a treatment option for patients with ESR1-mutated metastatic breast cancer in the second line.

Olema Pharmaceuticals is developing palazestrant, an oral SERD in phase 3 trials for ER+/HER2- metastatic breast cancer. Read why OLMA stock is a Hold.

An enzyme called cyclin-dependent kinase 2 (CDK2) regulates the cell cycle and may have the potential to drive therapeutic ...

Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) guidelines mark a significant milestone in breast cancer treatment, seamlessly ...